Dimeric erythropoietin fusion protein with enhanced erythropoietic activity in vitro and in vivo

Blood

Volumn 97, Issue 12, 2001, Pages 3776-3782

  Dalle, Bruno ^a,b   Henri, Annie ^a,b   Rouyer Fessard, Philippe ^a,b   Bettan, Mickaël ^a,b   Scherman, Daniel ^a,b   Beuzard, Yves ^a,b   Payen, Emmanuel ^a,b  

^a UNIVERSITÉ PARIS DIDEROT   (France)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; DIMER; HYBRID PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; DIMERIZATION; DRUG BLOOD LEVEL; DRUG MECHANISM; ERYTHROID CELL; HEMATOPOIETIC CELL; HORMONAL REGULATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0035877998     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.12.3776     Document Type: Article

References (41)

1. Jacobson L, Goldwasser E, Fried W, Plzak L. Role of the kidney in erythropoieisis [abstract]. Nature. 1957;179:633.
2. Lacombe C, Da Silva JL, Bruneval P, et al. Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J Clin Invest. 1988;81:620-623.
3. Bondurant MC, Koury MJ. Anemia induces accumulation of erythropoietin mRNA in the kidney and liver. Mol Cell Biol. 1986;6:2731-2733.
4. Koury MJ, Bondurant MC. Control of red cell production: the roles of programmed cell death (apoptosis) and erythropoietin. Transfusion. 1990;30:673-674.
5. Silva M, Grillot D, Benito A, et al. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood. 1996;88:1576-1582.
6. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med. 1987;316:73-78.
7. Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med. 1989;321:158-163.
8. Eschbach JW. Erythropoietin: the promise and the facts. Kidney Int Suppl. 1994;44:S70-S76.
9. Cazzola M, Mercuriali F, Brugnara C. Use of recombinant human erythropoietin outside the setting of uremia. Blood. 1997;89:4248-4267.
10. Leroy-Viard K, Rouyer-Fessard P, Beuzard Y. Improvement of mouse beta-thalassemia by recombinant human erythropoietin. Blood. 1991;78:1596-1602.
11. Vedovato M, Salvatorelli G, Taddei Masieri M, Vutto C. EPO serum levels in heterozygous beta-thalassemia. Haematologia (Budap). 1993;25:19-24.
12. Olivieri NF, Freedman MH, Perdne SP, et al. Trial of recombinant human erythropoietin: three patients with thalassemia intermedia. Blood. 1992;80:3258-3260.
13. Rachmilewitz EA, Goldfarb A, Dover G. Administration of erythropoietin to patients with beta-thalassemia intermedia: a preliminary trial. Blood. 1991;78:1145-1147.
14. Rachmilewitz EA, Aker M, Perry D, Dover G. Sustained increase in haemoglobin and RBC following long-term administration of recombinant human erythropoietin to patients with homozygous beta-thalassaemia. Br J Haematol. 1995;90:341-345.
15. Bourantas K, Economou G, Georgiou J. Administration of high doses of recombinant human erythropoietin to patients with beta-thalassemia intermedia: a preliminary trial. Eur J Haematol. 1997;58:22-25.
16. Kim CH, Oh Y, Lee TH. Codon optimization for high-level expression of human erythrepoietin (EPO) in mammalian cells. Gene. 1997;199:293-301.
17. Furst I. Amgen's NESP heats up competition in lucrative erythropoietin market [abstract]. Nat Biotechnol. 1997;15:940.
18. Wrighton NC, Farrell FX, Chang R, et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science. 1996;273:458-464.
19. Livnah O, Stura EA, Johnson DL, et al. Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science. 1996;273:464-471.
20. Wrighton NC, Balasubramanian P, Barbone FP, et al. Increased potency of an erythropoietin peptide mimetic through covalent dimerization. Nat Biotechnol. 1997;15;1261-1265.
21. Johnson DL, Farrell FX, Barbone FP, et al. Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity. Chem Biol. 1997;4:939-950.
22. Sytkowski AJ, Lunn ED, Davis KL, Feldman L, Siekman S. Human erythropoietin dimers with markedly enhanced in vivo activity. Proc Natl Acad Sci U S A. 1998;95:1184-1188.
23. Sytkowsk AJ, Lunn ED, Risinger MA, Davis KL. An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties. J Biol Chem. 1999;274:24773-24778.
24. Livnah O, Stura EA, Middleton SA, et al. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science. 1999;283:987-990.
25. Remy I, Wilson IA, Michnick SW. Erythropoietin receptor activation by a ligand-induced conformation change. Science. 1999;283:990-993.
26. Wen D, Boissel JP, Showers M, Ruch BC, Bunn HF. Erythropoietin structure-function relationships: identification of functionally important domains. J Biol Chem. 1994;269:22839-22846.
27. Matthews DJ, Topping RS, Cass RT, Giebel LB. A sequential dimerization mechanism for erythropoietin receptor activation. Proc Natl Acad Sci U S A. 1996;93:9471-9476.
28. Philo JS, Aoki KH, Arakawa T, Narhi LO, Wen J. Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: one high-affinity and one low-affinity interaction. Biochemistry. 1996;35:1681-1691.
29. Naffakh N, Henri A, Villeval JL, et al. Sustained delivery of erythropoietin in mice by genetically modified skin fibroblasts. Proc Natl Acad Sci U S A. 1995;92:3194-3198.
30. Shockett P, Difilippantonio M, Hellman N, Schatz DG. A modified tetracycline-regulated system provides autoregulatory, inducible gene expression in cultured cells and transgenic mice. Proc Natl Acad Sci U S A. 1995;92:6522-6526.
31. Sakaguchi M, Koishihara Y, Tsuda H, et al. The expression of functional erythrproietin receptors on an interleukin-3 dependent cell line. Biochem Biophys Res Commun. 1987;146:7-12.
32. Krystal G. A simple microassay for erythropoietin based on 3H-thymidine incorporation into spleen cells from phenylhydrazine-treated mice. Exp Hematol. 1983;11:649-660.
33. Freyssinier JM, Lecoq-Lafon C, Amsellem S, et al. Purification, amplification and characterization of a population of human erythroid progenitors. Br J Haematol. 1999;106:912-922.
34. Kreiss P, Bettan M, Crouzet J, Scherman D. Erythropoietin secretion and physiological effect in mouse after intramuscular plasmid DNA electrotransfer. J Gene Med. 1999;1:245-250.
35. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A. 1992;89:5547-5551.
36. Payen E, Bettan M, Rouyer-Fessard P, Beuzard Y, Scherman D. Improvement of mouse beta-thalassemia by electrotransfer of erythropoietin cDNA. Exp Hematol. 2001;29:295-300.
37. Rinsch C, Regulier E, Deglon N, et al. A gene therapy approach to regulated delivery of erythropoietin as a function of oxygen tension. Hum Gene Ther. 1997;8:1881-1889.
38. Dalle B, Payen E, Regulier E, et al. Improvement of mouse beta-thalassemia upon erythropoietin delivery by encapsulated myoblasts. Gene Ther. 1999;6:157-161.
39. Qiu H, Belanger A, Yoon HW, Bunn HF. Homodimerization restores biological activity to an inactive erythropoietin mutant. J Biol Chem. 1998;273:11173-11176.
40. Weinberg RS, Thomson JC, Lao R, Chen G, Alter BP. Stem cell factor amplifies newborn and sickle erythropoiesis in liquid cultures. Blood. 1993;81:2591-2599.
41. de Haan G, Dontie B, Engel C, Loeffler M, Nijhof W. In vivo effects of interleukin-11 and stem cell factor in combination with erythropoietin in the regulation of erythropoiesis. Br J Haematol. 1995;90:783-790.